POSC160 Economic Evaluation of Using Ribociclib in HER2- Negative Breast Cancer Patients: A Systematic Review of Evidence
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.562
https://www.valueinhealthjournal.com/article/S1098-3015(21)02357-3/fulltext
Title :
POSC160 Economic Evaluation of Using Ribociclib in HER2- Negative Breast Cancer Patients: A Systematic Review of Evidence
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02357-3&doi=10.1016/j.jval.2021.11.562
First page :
Section Title :
Open access? :
No
Section Order :
10100